List view / Grid view
28 August 2013 | By Carbon Trust
ABPI collaborates with the Carbon Trust to help pharmaceutical companies quickly estimate the carbon footprint of tablet medicines distributed in blister packs...
In this RMMs & Environmental Monitoring In-Depth Focus: The rapid microbiological methods revolution; Controlling contamination in the pharmaceutical industry; Rapid Micro Methods Roundtable...
BioWa, Inc. and Lonza today announced that they have entered into research agreements with Pfizer Inc. allowing the use of the POTELLIGENT® CHOK1SV Cell Line in the research and development of multiple proprietary antibodies in Pfizer’s pipeline.
29 July 2013 | By Pfizer
Pfizer announces reduced advance market commitment price with a further reduction beginning in 2014...
16 July 2013 | By Pfizer Inc.
Pfizer provides update on XELJANZ® (tofacitinib citrate) for the treatment of rheumatoid arthritis...
11 July 2013 | By Bristol-Myers Squibb Company
FDA accepted for review a sNDA for Eliquis®
10 July 2013 | By Pfizer
Prevenar 13* received European approval...
20 June 2013 | By A*STAR Institute of Chemical and Engineering Sciences (ICES)
New programme aims to increase productivity with technology solutions for pharmaceutical and chemical sectors...
6 May 2013 | By Bristol-Myers Squibb Company
ARISTOTLE studied Eliquis vs. warfarin...
29 April 2013 | By Merck
Agreement to develop and commercialize Ertugliflozin, an investigational medicine for type 2 diabetes...
28 April 2013 | By Pfizer
Pfizer presented the results from a Phase 3 study...
25 April 2013 | By Pfizer
Pfizer intends to appeal and seek re-examination...
10 April 2013 | By Pfizer
Palbociclib has received Breakthrough Therapy designation...
3 April 2013 | By Pfizer
CHOP and Pfizer are joining forces...
28 March 2013 | By Pfizer
“I’m delighted the EC has approved BOSULIF..."
